PU21.03 Assessment of crosslinker suitability for fusion peptide conjugates as priming immunogens for an HIV-1 vaccinePublication OnlyNovel vaccine and other prevention approaches
PU21.06 DNA vs ChAd-vectored vaccines as priming vaccines in heterologous prime-boost regimens to increase HTI immunogenicity in micePublication OnlyNovel vaccine and other prevention approaches
PU21.08 Distinct classes of HIV-1 cross-clade neutralizing antibodies targeting fusion peptide elicited in mice by diverse immunization regimensPublication OnlyNovel vaccine and other prevention approaches
PU23.03 Being a part of the conversation: capacitating youth to participate in HIV prevention conversations using a digital citizen engagement platform in South AfricaPublication OnlyPolicy and advocacy
PU23.04 Lessons learned from the strategic agenda for key populations: Experiences from BrazilPublication OnlyPolicy and advocacy
PU24.01 Birth microbiota in HIV-exposed-uninfected infants cause changes in innate and adaptive immune compartments in a murine modelPublication OnlyPreclinical studies for HIV prevention
PU25.01 Social disclosures in relation to perceived HIV protection provided by the dapivirine vaginal ringPublication OnlyPreclinical studies for HIV prevention
PU25.02 Correlates of adherence to the dapivirine vaginal ring for HIV-1 preventionPublication OnlyProduct acceptability and adherence
PU25.03 Health care providers' preferences about an MPT implant: insights from South Africa and Zimbabwe on the Subcutaneous Contraceptive HIV Implant Engineered for Long-acting Delivery (SCHIELD) StudyPublication OnlyProduct acceptability and adherence
PU26.01 Quality and turnaround times of PMTCT viral load monitoring under Option B+ in six South African districts with high antenatal HIV burdenPublication OnlyTesting: technology, coverage, viral load, point of care and CD4 count
seek-warrow-warrow-eseek-e431 - 440 of 444 items